Detailed price information for Gain Therapeutics Inc (GANX-Q) from The Globe and Mail including charting and trades.

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...

SCOUT-HCM demonstrated the superiority of Camzyos on the primary endpoint and multiple secondary endpointsThe overall safety results in this study were consistent with the established safety profile ...

A research team presents an overview of recent advances in the microbial biosynthesis of L-tryptophan (L-Trp) and its ...

Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 ––Total ...

Foresee licenses exclusive global rights related to its MMP-12 inhibitor programs to Primevera Therapeutics, LLC.Foresee will receive a 10 million USD ...

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

Foresee licenses exclusive global rights related to its MMP-12 inhibitor programs to Primevera Therapeutics, LLC.Foresee will receive a 10 million USD upfront payment, potential milestones of ...

This review synthesizes progress in pathway optimization, regulatory rewiring, and microbial cell factory design that has ...

Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimabSAN ...

Standard Western medicine is reactive medicine. It primarily focuses on diagnosing and treating symptoms and diseases using ...